Skip to main content
U.S. flag

An official website of the United States government

FTD: Biomarker development (Milestone 9.Q)

In Progress

Timeline Start - End

2016 - 2027

Research Implementation Area


AD-Related Dementias Focus

Develop an array of FTD biomarkers for diagnosis, prediction, disease monitoring, target engagement, and patient stratification for clinical trials. 

Success Criteria

  • At least two new FTD biomarkers that are validated for clinical trials, including in at least two populations that experience health disparities. 

Summary of Key Accomplishments

A public-private biomarkers consortium led by the Foundation for NIH (FNIH) is evaluating neurofilament light chain protein as a biomarker for neurodegeneration in familial forms of FTD. Additionally, an NIH-led proteinopathy consortium has defined the atomic structure of various forms of proteins like Tau that are aggregated in FTD and unveiling promising targets for PET imaging development. In addition, relatively simple blood tests now have the ability to distinguish FTD from other dementias like Alzheimer's, which will be critical for future targeted clinical trials and has the promise of being a relatively inexpensive test that could be more readily applied to underserved populations. Finally, supplemental studies to the large ALLFTD cohort include the use of mobile apps as well as in-home, non-invasive measurements and trackers that have the promise of monitoring the progression of FTD in a highly sensitive manner and directly in an individual's home rather than needing to travel to a clinical research site.

The key accomplishments summary is current as of July 2022.  

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health